295 related articles for article (PubMed ID: 16540354)
61. Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females.
Cazzola M; May A; Bergamaschi G; Cerani P; Rosti V; Bishop DF
Blood; 2000 Dec; 96(13):4363-5. PubMed ID: 11110715
[TBL] [Abstract][Full Text] [Related]
62. Pyridoxine-refractory congenital sideroblastic anaemia with evidence for autosomal inheritance: exclusion of linkage to ALAS2 at Xp11.21 by polymorphism analysis.
Jardine PE; Cotter PD; Johnson SA; Fitzsimons EJ; Tyfield L; Lunt PW; Bishop DF
J Med Genet; 1994 Mar; 31(3):213-8. PubMed ID: 7912287
[TBL] [Abstract][Full Text] [Related]
63. Intron 1 GATA site enhances ALAS2 expression indispensably during erythroid differentiation.
Zhang Y; Zhang J; An W; Wan Y; Ma S; Yin J; Li X; Gao J; Yuan W; Guo Y; Engel JD; Shi L; Cheng T; Zhu X
Nucleic Acids Res; 2017 Jan; 45(2):657-671. PubMed ID: 28123038
[TBL] [Abstract][Full Text] [Related]
64. A novel mutation in exon 5 of the ALAS2 gene results in X-linked sideroblastic anemia.
Hurford MT; Marshall-Taylor C; Vicki SL; Zhou JZ; Silverman LM; Rezuke WN; Altman A; Tsongalis GJ
Clin Chim Acta; 2002 Jul; 321(1-2):49-53. PubMed ID: 12031592
[TBL] [Abstract][Full Text] [Related]
65. Autosomal dominant iron overload due to a novel mutation of ferroportin1 associated with parenchymal iron loading and cirrhosis.
Wallace DF; Clark RM; Harley HA; Subramaniam VN
J Hepatol; 2004 Apr; 40(4):710-3. PubMed ID: 15030991
[TBL] [Abstract][Full Text] [Related]
66. A novel mutation of the erythroid-specific gamma-Aminolevulinate synthase gene in a patient with non-inherited pyridoxine-responsive sideroblastic anemia.
Harigae H; Furuyama K; Kudo K; Hayashi N; Yamamoto M; Sassa S; Sasaki T
Am J Hematol; 1999 Oct; 62(2):112-4. PubMed ID: 10577279
[TBL] [Abstract][Full Text] [Related]
67. Identification of a highly polymorphic marker within intron 7 of the ALAS2 gene and suggestion of at least two loci for X-linked sideroblastic anemia.
Cox TC; Kozman HM; Raskind WH; May BK; Mulley JC
Hum Mol Genet; 1992 Nov; 1(8):639-41. PubMed ID: 1301172
[TBL] [Abstract][Full Text] [Related]
68. The molecular biology and pyridoxine responsiveness of X-linked sideroblastic anaemia.
May A; Bishop DF
Haematologica; 1998 Jan; 83(1):56-70. PubMed ID: 9542324
[TBL] [Abstract][Full Text] [Related]
69. GLRX5 mutations impair heme biosynthetic enzymes ALA synthase 2 and ferrochelatase in Human congenital sideroblastic anemia.
Daher R; Mansouri A; Martelli A; Bayart S; Manceau H; Callebaut I; Moulouel B; Gouya L; Puy H; Kannengiesser C; Karim Z
Mol Genet Metab; 2019 Nov; 128(3):342-351. PubMed ID: 30660387
[TBL] [Abstract][Full Text] [Related]
70. X-linked sideroblastic anaemia in a female fetus: a case report and a literature review.
Nzelu D; Shangaris P; Story L; Smith F; Piyasena C; Alamelu J; Elmakky A; Pelidis M; Mayhew R; Sankaran S
BMC Med Genomics; 2021 Dec; 14(1):296. PubMed ID: 34930268
[TBL] [Abstract][Full Text] [Related]
71. Iron overload in patients with sideroblastic anaemia is not related to the presence of the haemochromatosis Cys282Tyr and His63Asp mutations.
Beris P; Samii K; Darbellay R; Zoumbos N; Tsoplou P; Kourakli A; Preud'homme C; Fenaux P
Br J Haematol; 1999 Jan; 104(1):97-9. PubMed ID: 10027719
[TBL] [Abstract][Full Text] [Related]
72. The effect of the metabolic syndrome, hepatic steatosis and steatohepatitis on liver fibrosis in hereditary hemochromatosis.
Adams LA; Angulo P; Abraham SC; Torgerson H; Brandhagen D
Liver Int; 2006 Apr; 26(3):298-304. PubMed ID: 16584391
[TBL] [Abstract][Full Text] [Related]
73. [Hemochromatosis associated with primary sideroblastic anemia].
Guañabens Calvet C; Soler Roca J; Brunet Mauri S; Binimelis Vidal J; Gimferrer Felip E; Domingo Albós A; Pujol-Moix N
Sangre (Barc); 1984; 29(5):887-91. PubMed ID: 6523341
[No Abstract] [Full Text] [Related]
74. X-linked sideroblastic anemia due to carboxyl-terminal ALAS2 mutations that cause loss of binding to the β-subunit of succinyl-CoA synthetase (SUCLA2).
Bishop DF; Tchaikovskii V; Hoffbrand AV; Fraser ME; Margolis S
J Biol Chem; 2012 Aug; 287(34):28943-55. PubMed ID: 22740690
[TBL] [Abstract][Full Text] [Related]
75. A synonymous coding variant that alters ALAS2 splicing and causes X-linked sideroblastic anemia.
Oakley JH; Campagna DR; Sun L; Rockowitz S; Sliz P; Boudreaux J; Woods G; Fleming MD
Pediatr Blood Cancer; 2022 Jan; 69(1):e29309. PubMed ID: 34411431
[No Abstract] [Full Text] [Related]
76. Molecular defects of erythroid 5-aminolevulinate synthase in X-linked sideroblastic anemia.
Bottomley SS; May BK; Cox TC; Cotter PD; Bishop DF
J Bioenerg Biomembr; 1995 Apr; 27(2):161-8. PubMed ID: 7592563
[TBL] [Abstract][Full Text] [Related]
77. A hemizygous p.R204Q mutation in the ALAS2 gene underlies X-linked sideroblastic anemia in an adult Chinese Han man.
Huang J; Ge M; Shao Y; Wang M; Jin P; Huo J; Li X; Zhang J; Nie N; Zheng Y
BMC Med Genomics; 2021 Apr; 14(1):107. PubMed ID: 33858445
[TBL] [Abstract][Full Text] [Related]
78. Multiple mechanisms for hereditary sideroblastic anemia.
Furuyama K; Sassa S
Cell Mol Biol (Noisy-le-grand); 2002 Feb; 48(1):5-10. PubMed ID: 11929048
[TBL] [Abstract][Full Text] [Related]
79. Hepatic iron overload and hepatocellular carcinoma.
Kew MC
Cancer Lett; 2009 Dec; 286(1):38-43. PubMed ID: 19081672
[TBL] [Abstract][Full Text] [Related]
80. Type 3 hereditary hemochromatosis in a patient from sub-Saharan Africa: is there a link between African iron overload and TFR2 dysfunction?
Majore S; Ricerca BM; Radio FC; Binni F; Cosentino I; Gallusi G; De Bernardo C; Morrone A; Grammatico P
Blood Cells Mol Dis; 2013 Jan; 50(1):31-2. PubMed ID: 22981443
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
